Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease

The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are: * Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice? * What is the safety profile and treatment persistence of IL-23 inhibitors in this population? * Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.

NCT Number	NCT07448402
Lead Sponsor	Caja Costarricense de Seguro Social
Conditions	Psoriasis, Psoriasis Arthritis, Psoriasis (PsO)
Enrollment	50 participants
Start Date	2026-05
Primary Completion	2031-05 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-03-09